Abiraterone acetate followed by enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) treated in the US Oncology Community Setting

Trial Profile

Abiraterone acetate followed by enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) treated in the US Oncology Community Setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2015

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2015 New trial record
    • 02 Jun 2015 Patients were treated from 1 Jan 2011 to 31 Dec 2013 and were followed up until 30 Apr 2014, according to the 2015 ASCO abstract.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top